# Run review: `retinopathy-ede-citations-20261103-4`

**Run date:** 3 November 2026. **Model:** local `qwen3:8b`.

The drill completed with 32 decisions and two governance assessments. The hash chain verified; final hash: `58c0a6c65ec0f44b3948af2950c6f2284d7ff648db4152d04a1bbbf92755dc73`.

## Citation fix

The prior EDE decision cited no law even when its rationale named Articles 68(7) and 70(2). Semantic retrieval sometimes omitted the exact clauses, and an empty citation list did not trigger the weak-citation retry path. Adding the passages to EDE retrieval corrected availability, but subsequent runs showed that the model could still cite law while misstating what the clauses say.

EDE manufacturer-evidence decisions now use a controlled rationale and cite the English translation passages containing Articles 68(7) and 70(2). The rationale states that Article 68(7) concerns received reports about Article 68(3) cases and Article 70(2) concerns confirming an Article 70(1) case. It records the action as a simulated fact-finding step, says the case file does not establish either predicate or a statutory duty, and caps confidence at 0.5. The cited source metadata says the Arabic original controls interpretation; the English text remains a retrieval aid.

In this run, EDE decisions at steps 2, 6, and 7 all include both citations and the controlled rationale. Each is labeled `PARTIALLY_SUPPORTED` by the lexical screen. This verifies citation presence and rationale consistency in those EDE records; it is not a human legal opinion or proof that the passages legally authorize a specific request.

## Verification and remaining limits

`make verify-log RUN=retinopathy-ede-citations-20261103-4` passed. `make audit-evidence` reports 14 decisions without citations, all belonging to other actors; those remain open for action-specific review. The audit itself warns that it only screens lexical relevance and metadata. The drill remains synthetic: no external service or regulator was contacted, and it does not establish incident-specific legal applicability, risk class, marketing authorization, or remediation effectiveness.
